Aclaris Therapeutics to Participate in the Jefferies Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics, a clinical-stage biopharmaceutical firm focused on immuno-inflammatory diseases, announced that Dr. Neal Walker, President and CEO, will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 11:30 a.m. ET in New York. The session will also allow for 1x1 meetings on the same day. A live webcast of the chat will be available on Aclaris’ website and archived for 30 days. The company is known for its innovative drug candidates aimed at addressing unmet patient needs in this therapeutic area.
Details
News Market Reaction – ACRS
The recorded move for ACRS in the trading session of this news was +8.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 11:30 a.m. ET in New York, New York. Management will be available June 8th for 1x1 meetings.
A live webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Contact
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.